Downgrade Alert for Fresenius Medical Care (FMS)
Fresenius Medical Care (NYSE:FMS) was downgraded from Buy to Neutral at UBS today. The stock closed yesterday at $37.95 on volume of 83,000 shares, below average daily volume of 117,000.
There is potential upside of 0.4% for shares of Fresenius Medical Care based on a current price of $37.95 and an average consensus analyst price target of $38.11. The stock should find initial support at its 50-day moving average (MA) of $36.78 and further support at its 200-day MA of $34.76.
In the past 52 weeks, Fresenius Medical Care share prices have been bracketed by a low of $31.28 and a high of $38.19 and closed yesterday at $37.95, 21% above that low price. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has remained constant.
Fresenius Medical Care AG & Co. KGaA offers kidney dialysis services and manufactures and distributes equipment and products used in the treatment of dialysis patients. The Company also offers clinical laboratory testing and diagnostic testing services and provides home infusion, respiratory therapy, ultrasound, and echo-cardiography. Fresenius operates worldwide.
SmarTrend recommended that subscribers consider buying shares of Fresenius Medical Care on October 24th, 2014 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $35.79. Since that recommendation, shares of Fresenius Medical Care have risen 6.0%. We continue to monitor FMS for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: analyst upgrades/downgrades fresenius medical care